FCCC LOGO Faculty Publications
Boente MP
Oncology. Ovarian cancer: surgical aspects of patient care
Journal of Care Management.. 1999 Feb;5(1) :Disease Manage Digest: 4-5
Back to previous list
Special Fields Contained : cited references. Special Interest Category: Case Management Special Interest Category: Oncologic Care Local Message: Locally Held: No Entry Week: 199904 Cited References: American Cancer Society. Cancer Facts & Figures -- 1999. Cited References: Boente MP, Chi DS, Hoskins WJ et al. The role of surgery in the management of ovarian cancer: Primary and interval cytoreductive surgery. Semin Oncol 1998; 25:326-334. Cited References: Ozols RF, Rubin SC, Thomas G et al. Epithelial ovarian cancer, in Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynecologic Oncology. (ed 2) pp 919-986. Philadelphia, PA, Lippincott-Raven; 1997. Cited References: Griffiths CT. Surgery at the time of diagnosis in ovarian cancer, in Blackledge G, Chan KK (eds): Management of Ovarian Cancer. pp 60-75. London, Butterworth and Co; 1986. Cited References: McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer. N Engl J Med 1996; 334:1-6. Cited References: McGuire WP, Hoskins WJ, Brady MF et al. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal Stage III and Stage IV ovarian cancer: A Gynecologic Oncology Group study. Semin Oncol 1997; 24 (Suppl 2):S213-S216. Cited References: Bertelsen K, Kaem J, Simonsen E et al. Is cisplatin-Taxol the standard treatment in advanced ovarian cancer? A Phase III randomized trial performed by the EORTC Gynecologic Cancer Cooperative Group, the Nordic Ovarian Cancer Group, the NCI-Canada Clinical Trials Group, and the Scottish Gynecologic Cancer Study Group Abstract 614. Eur J Cancer 1997; 33(8):S138. Cited References: Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17:409-422.